Zomedica Corp.

0.10
0.00 (2.56%)
At close: Mar 04, 2025, 9:50 AM

Company Description

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals.

The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals.

It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and markets a novel pathogen detection system.

The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020.

Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.

Zomedica Corp.
Zomedica Corp. logo
Country United States
IPO Date Nov 21, 2017
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 144
CEO Larry C. Heaton II

Contact Details

Address:
100 Phoenix Drive
Ann Arbor, Michigan
United States
Website https://www.zomedica.com

Stock Details

Ticker Symbol ZOM
Exchange AMEX
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001684144
CUSIP Number 98980M109
ISIN Number CA98980M1095
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
Larry C. Heaton II President, Chief Executive Officer & Director
Anthony K. Blair Chief Operating Officer
Scott A. Jordan EVice President of Finance & Chief Financial Officer
Greg Blair Senior Vice President of Business Development & Strategic Planning
Karen L. DeHaan-Fullerton J.D. General Counsel & Corporate Secretary
Kristin Domanski Vice President of Human Resources
Mike Zuehlke Vice President of Finance & Corporate Controller
Nicole Westfall M.B.A. Senior Vice President of Marketing
Robert W. DiMarzo Consultant
Russell Kevin Klass Senior Vice President of Sales

Latest SEC Filings

Date Type Title
Mar 05, 2025 8-K Current Report
Feb 24, 2025 4 Filing
Jan 03, 2025 4 Filing
Jan 03, 2025 3 Filing
Dec 19, 2024 8-K Current Report
Nov 26, 2024 4/A [Amend] Filing
Nov 19, 2024 8-K Current Report
Nov 13, 2024 4 Filing
Nov 13, 2024 4 Filing
Nov 13, 2024 4 Filing